We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE).
- Authors
Degl'Innocenti, A.; Elmfeldt, D.; Hofman, A.; Lithell, H.; Olofsson, B.; Skoog, I.; Trenkwalder, P.; Zanchetti, A.; Wiklund, I.
- Abstract
The Study on COgnition and Prognosis in the Elderly (SCOPE) was a multinational, randomised, double-blind study to assess the effects of candesartan 8-16?mg daily on cardiovascular events and cognitive function in elderly patients (aged 70-89 years) with mild to moderate hypertension. A total of 4937 patients were randomised to candesartan or placebo with other antihypertensive drugs (mostly diuretics, beta-blockers, and calcium antagonists) added as needed to control blood pressure. Only 16% of the patients in the control group received placebo alone. The mean follow-up was 3.7 years. The aim of this health-related quality of life (HRQL) substudy analysis was to investigate changes in HRQL during antihypertensive treatment, and possible differences in patients receiving candesartan-based or other antihypertensive treatment. Three validated HRQL instruments were used: the Psychological General Well-being (PGWB) Index, the Subjective Symptoms Assessment Profile (SSA-P), and the EuroQoL Health Utility Index (EuroQoL). The HRQL was generally good at baseline and well preserved during follow-up in the presence of substantial blood pressure reductions in both treatment groups. Several of the observed changes in score from baseline to last visit favoured candesartan-based compared to control treatment, particularly the changes in PGWB Anxiety (-0.5 vs -1.0, P=0.01), PGWB Positive well-being (-0.8 vs -1.1, P=0.04), SSA-P Cardiac symptoms (0.03 vs 0.10, P=0.03), and EuroQoL Current health (-3.1 vs -5.3, P=0.008). This favourable result may be related to the somewhat lower blood pressure associated with candesartan-based treatment. In conclusion, there should be no reason to withhold modern antihypertensive therapy in elderly patients due to concerns for a negative effect on HRQL.Journal of Human Hypertension (2004) 18, 239-245. doi:10.1038/sj.jhh.1001657
- Subjects
COGNITION; PROGNOSIS; CARDIOVASCULAR diseases; ADRENERGIC beta blockers; BLOOD pressure; ANTIHYPERTENSIVE agents; ANXIETY
- Publication
Journal of Human Hypertension, 2004, Vol 18, Issue 4, p239
- ISSN
0950-9240
- Publication type
Article
- DOI
10.1038/sj.jhh.1001657